Sanmao Kang

Title: Sanmao Kang: Innovator in Oncolytic Adenovirus Research

Introduction

Sanmao Kang is a prominent inventor based in Hangzhou, China. He has made significant contributions to the field of biotechnology, particularly in the development of innovative treatments for tumors and cancers. His work focuses on the use of oncolytic adenoviruses, which have the potential to revolutionize cancer therapy.

Latest Patents

Sanmao Kang holds a patent for an isolated recombinant oncolytic adenovirus, along with pharmaceutical compositions and their uses for drug treatment of tumors and cancers. The patent describes a selectively replicating oncolytic adenovirus that integrates a coding sequence of exogenous shRNA capable of inhibiting PDL1 expression in tumor cells. This innovative approach allows the virus to replicate more effectively in tumor cells compared to normal primary cells. The expressed shPDL1 significantly reduces the level of PDL1 protein in tumor cells, enhancing the oncolytic killing effect of the virus and stimulating an anti-tumor immune response.

Career Highlights

Sanmao Kang is associated with Hangzhou Converd Co., Ltd., where he continues to advance his research in oncolytic virus therapies. His work has garnered attention for its potential to improve cancer treatment outcomes. He has been instrumental in developing novel therapeutic strategies that leverage the unique properties of oncolytic adenoviruses.

Collaborations

Sanmao Kang collaborates with notable colleagues, including Jipo Sheng and Jin Fu. Their combined expertise contributes to the innovative research environment at Hangzhou Converd Co., Ltd.

Conclusion

Sanmao Kang's contributions to the field of biotechnology, particularly in the development of oncolytic adenoviruses, highlight his role as a leading inventor in cancer treatment research. His innovative approaches have the potential to significantly impact the future of oncology.